Skip to main content

Table 1 Demographic features, types of idiopathic inflammatory myopathies, autoantibody distribution and therapy of 38 patients immediately before rituximab application (Baseline)

From: Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies

Parameters N = 38
Current age (years) 42.6 ± 10.9
Female gender 32 (84.2)
White ethnicity 26 (68.4)
Disease duration (years) 3.0 (2.0–6.5)
Duration time: diagnosis - symptom onset (months) 4.5 (3.9–9.0)
Idiopathic inflammatory myopathies
 Dermatomyositis 15 (39.5)
 Polymyositis 10 (26.3)
 Antisynthetase syndrome 13 (34.2)
Autoantibodies
 Antinuclear factor 31 (81.6)
 Anti-Ro-52 16 (42.1)
 Anti-Jo-1 13 (34.2)
 Anti-Mi-2 4 (10.5)
 Anti-OJ 0
 Anti-EJ 0
 Anti-PL-7 0
 Anti-PL-12 0
Prednisone dose (mg/day) 18.8 (10.0–36.3)
Methylprednisolone + intravenous human immunoglobulin pulse therapy 23 (60.5)
  1. Results expressed as mean ± standard deviation, median (25th - 75th interquartile range) or frequency (%)